<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072407</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-PB119-US01-01</org_study_id>
    <nct_id>NCT03072407</nct_id>
  </id_info>
  <brief_title>MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PegBio Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PegBio Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a phase 1, randomized, double-blind, placebo-controlled, sequential parallel group,
      MAD study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of four
      once-weekly subcutaneous doses of PB-119 to subjects with T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose levels of 25 µg, 50 µg, 100 µg and 200 µg with a dosing regimen of once weekly for 4
      consecutive weeks will be evaluated
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2015</start_date>
  <completion_date type="Actual">November 15, 2016</completion_date>
  <primary_completion_date type="Actual">November 2, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-control , parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of AEs and the finding from the physical examination, the abnormal lab results</measure>
    <time_frame>accessed up to 4 weeks</time_frame>
    <description>include monitoring of AEs, vital signs (blood pressure, pulse rate, respiratory)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PB-119 blood plasma concentration</measure>
    <time_frame>accessed up to 4 weeks</time_frame>
    <description>to collect PB-119 blood plasma concentration of the subjects who use PB-119 intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PB-119 antibody</measure>
    <time_frame>accessed up to 4 weeks</time_frame>
    <description>the number of subjects who are with positive antibody results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity (SI)</measure>
    <time_frame>accessed up to 4 weeks</time_frame>
    <description>be estimated from glucose and insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-cell Responsivity Index</measure>
    <time_frame>accessed up to 4 weeks</time_frame>
    <description>be estimated from serum glucose and c-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>accessed up to 4 weeks</time_frame>
    <description>be calculated for each individual subject as the product of SI and Φtotal</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PB-119 injection placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 injection 25ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 injection 50ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 injection 100ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PB-119 injection 200ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PB-119 injection</intervention_name>
    <arm_group_label>PB-119 injection 25ug</arm_group_label>
    <arm_group_label>PB-119 injection 50ug</arm_group_label>
    <arm_group_label>PB-119 injection 100ug</arm_group_label>
    <arm_group_label>PB-119 injection 200ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PB-119 injection placebo</intervention_name>
    <arm_group_label>PB-119 injection placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients in whom T2DM has been diagnosed for at least 3 months prior to screening and
             have not been taking any treatment but have made lifestyle modifications (i.e., diet
             and exercise) for at least 4 weeks or are taking metformin (with no change in the
             treatment including dose over the past 2 months).

          2. In good general health as determined by the investigator at screening evaluation

          3. Male and/or female subjects between the ages of 18 and 70 years, inclusive;

          4. Are capable of giving informed consent and complying with study procedures;

          5. Body Mass Index (BMI) of approximately 22 to 40 kg/m2;

          6. Fasting C-peptide test result must be &gt;0.4 nmol/L;

          7. HbA1c ≥6.5 % and ≤12%;

          8. Female subjects must have a negative urine pregnancy test result prior to enrollment.

          9. Nonsmoker,

         10. Willing and able to adhere to study restrictions and to be confined at the clinical
             research center.

        Exclusion Criteria:

          1. Subjects with a personal or family history of medullary thyroid carcinoma (MTC) or in
             subjects with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);

          2. Screening fasting blood glucose ≤100 or ≥270 mg/dL

          3. Type 1 diabetes mellitus, or latent autoimmune diabetes in adults; diabetic
             neuropathy, retinopathy or nephropathy;

          4. Previous treatment with an approved or investigational GLP-1 mimetic;

          5. Patients treated with any investigational drugs within 6 weeks of screening;

          6. Subjects with pancreatitis;

          7. Clinically significant gastrointestinal disorder

          8. History or symptoms of clinically significant cardiovascular disease, particularly
             coronary artery disease, arrhythmias, atrial tachycardia,

          9. Uncontrolled hypertension at screening;

         10. History of clinically significant central nervous system disease including: transient
             ischemic attack, stroke, seizure disorder, depression,

         11. History of liver disease

         12. History of clinically significant renal disease

         13. Uncontrolled severe dyslipidemia;

         14. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg), or hepatitis C antibody;

         15. A hospital admission or major surgery within 30 days prior to screening;

         16. A history of prescription drug abuse, or illicit drug use within 6 months prior to
             screening;

         17. A history of alcohol abuse according to medical history within 6 months prior to
             screening;

         18. A positive screen for alcohol, or drugs of abuse;

         19. An unwillingness or inability to comply with food and beverage restrictions during
             study participation;

         20. Use of prescription or over-the-counter (OTC) medications, and herbal An

         21. Unwillingness of male participants to use appropriate contraceptive measures if
             engaging in sexual intercourse with a female partner of childbearing potential.
             Appropriate measures include use of a condom and spermicide and, for female partners,
             use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives,
             injectable progesterone, progesterone subdermal implants, or a tubal ligation. Sexual
             intercourse with pregnant or lactating women is prohibited
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Tracey, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Frontage Clinical Services,Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontage Clinical Services. Inc.</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

